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SUMMARY
APOBEC3B cytosine deaminase activity has recently
emerged as a significant mutagenic factor in human
cancer. APOBEC activity is induced in virally infected
cells, and APOBEC signaturemutations occur at high
frequency in cervical cancers (CESC), over 99% of
which are caused by human papillomavirus (HPV).
We tested whether APOBEC-mediated mutagenesis
is particularly important in HPV-associated tumors
by comparing the exomes of HPV+ and HPV head
and neck squamous cell carcinomas (HNSCCs)
sequenced by The Cancer Genome Atlas project.
As expected, HPV HNSCC displays a smoking-
associated mutational signature, whereas our data
suggest that reduced exposure to exogenous carcin-
ogens in HPV+ HNSCC creates a selective pressure
that favors emergence of tumors with APOBEC-
mediated driver mutations. Finally, we provide evi-
dence that APOBEC activity is responsible for
the generation of helical domain hot spot mutations
in the PIK3CA gene across multiple cancers.
Our findings implicate APOBEC activity as a key
driver of PIK3CA mutagenesis and HPV-induced
transformation.
INTRODUCTION
The apolipoprotein B mRNA editing enzyme catalytic polypep-
tide-like (APOBEC) family of enzymes catalyze the deamination
of cytosine bases in nucleic acids, resulting in conversion of
the target cytosine to uracil and thus an alteration of the
substrate DNA or RNA sequence (Conticello, 2008). Depending
upon the repair pathway used to remove and replace the result-
ing uracil base, cytosine deamination in DNA most commonly
results in mutations to thymine or guanine (Roberts et al.,
2012; Simonelli et al., 2005). One APOBEC family member, the
activation-induced deaminase (AID), is expressed in B lympho-
cytes, wherein it participates in the processes of somatic
hypermutation and class switch recombination key to antibody
generation (Pham et al., 2005), whereas another, APOBEC3G,
participates in the response to infection by HIV and other retro-
viruses, acting on viral cDNA to elicit mutagenesis of the viral
genome (Harris et al., 2003; Mangeat et al., 2003; Zhang et al.,
2003). APOBEC3 enzymes also participate in the response to
DNA viruses, including human papillomavirus (HPV) and hepati-
tis virus B (HBV) (Vartanian et al., 2008, 2010). A number of
studies have suggested a role for APOBECs in carcinogenesis:
both AID and APOBEC1 promote tumorigenesis in transgenic
mouse models, and AID upregulation by Helicobacter pylori
has also been shown to generate TP53 mutations in gastric
epithelial cells (Matsumoto et al., 2007; Okazaki et al., 2003;
Yamanaka et al., 1995). Analysis of sequence data from human
tumors revealed clusters of strand-specific cytosine mutations
suggestive of APOBEC editing of cellular DNA, a process termed
kataegis (Nik-Zainal et al., 2012), likely resulting from APOBEC-
mediated deamination of single-stranded DNA generated during
repair of double-strand DNA breaks (Nik-Zainal et al., 2012;
Roberts et al., 2012).
Many of the cytosine mutations characteristic of kataegis fit
the consensus target site for a subset of APOBECs, collectively
termed ‘‘TC-specific APOBECs,’’ that display preference for
thymine immediately 50 to the target cytosine (Roberts et al.,
2012). Studies on deamination of retroviral cDNA and on recom-
binant APOBEC3B indicate a preference for adenine, thymine,
or guanine immediately 30 to the target cytosine (Bishop et al.,
2004; Burns et al., 2013b). However, C > T mutations also occur
via the spontaneous deamination of methylated CpG sites, a
mutational process that has been linked to aging (Alexandrov
et al., 2013a). The use of ‘‘TCWmutations’’ (C > T and C > Gmu-
tations at T-C-A/T [TCW] trinucleotides) to evaluate APOBEC-
mediated mutagenesis avoids this confounding factor (Roberts
et al., 2013). Furthermore, TCW mutations are enriched within
kataegis clusters and near to rearrangement breakpoints—
both indicative of APOBEC involvement (Drier et al., 2013;
Nik-Zainal et al., 2012; Roberts et al., 2012). Two recent ana-
lyses of such APOBEC signature mutations in whole-exome
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(all known coding regions of the genome) sequence data from
The Cancer Genome Atlas (TCGA) suggest cytosine deamina-
tion catalyzed by APOBEC enzymes is a mutagenic mechanism
in multiple cancer types (Burns et al., 2013b; Roberts et al.,
2013). Of the TC-specific APOBECs, APOBEC3B has been
posited to play the prominent role in this process, due to its
localization to the nuclei of interphase cells and correlation
with cytosine mutations in breast and ovarian cancer (Burns
et al., 2013a, 2013b; Leonard et al., 2013). Among those cancers
with the highest APOBEC3B mRNA levels and greatest fraction
of TCW mutations are cervical and head and neck squamous
cell carcinomas (CESC and HNSCC, respectively). CESC and
HNSCC were also among 16 cancer types reported by Stratton
and colleagues to display the putative APOBEC mutational
signature (Alexandrov et al., 2013a). Over 99% of CESCs and
a subset of HNSCCs are caused by high-risk variants of HPV
(Chaturvedi et al., 2011; Ramqvist and Dalianis, 2010; Wal-
boomers et al., 1999). The majority of HNSCCs, meanwhile,
are unrelated to HPV and typically occur in heavy smokers. Of
relevance to our findings, sequencing of CESC and HNSCC
has revealed that the PIK3CA proto-oncogene is mutated at
high frequency in these tumors. Indeed, in some HPV+
HNSCCs, it was the only mutation observed among a large
panel of known cancer genes (Lechner et al., 2013b; Lui et al.,
2013; Ojesina et al., 2014). The established role of APOBEC en-
zymes in antiviral responses, together with the finding of such
high levels of APOBEC signature mutations in CESC has led to
the proposal that APOBEC-mediated mutagenesis may play a
particular role in the development of virally driven cancers (Alex-
androv et al., 2013a; Kuong and Loeb, 2013; Ojesina et al., 2014;
Roberts et al., 2013). Analyzing HNSCC enabled direct compar-
ison of exomes from 40 HPV+ and 258 HPV tumors arising at
similar sites from a single study. We were therefore able to test
our hypothesis that it is the HPV+ tumors in which APOBEC
activity accounts for the greatest proportion of mutations and
to establish a clear link between HPV-driven tumorigenesis
and APOBEC-mediated mutagenesis.
RESULTS
Mutations Characteristic of APOBEC Activity Are
Enriched in HPV+ HNSCC
Recent work on the detection of viral gene expression in TCGA
samples using RNA sequencing (RNA-seq) data permitted
definitive identification of HPV status for 299 samples in the
TCGA HNSCC cohort (Chen et al., 2013; Tang et al., 2013).
We retrieved RNA-seq and somatic mutation data (see Experi-
mental Procedures) and analyzed the mutational signatures
present in these samples. A separate HNSCC cohort was previ-
ously shown to harbor four mutational signatures, implicating
APOBEC activity, age, tobacco smoking, and exposure to ultra-
violet light as the factors responsible for the majority of muta-
tions in these tumors (Alexandrov et al., 2013a). The TCGA
HNSCC data set that we analyzed contains only one surface-
exposed tumor, a lip squamous cell carcinoma, that we
removed from our analysis to eliminate UV as a potential con-
founding source of C > T mutations (Pfeifer et al., 2005). Using
the method of Alexandrov and colleagues (Alexandrov et al.,
2013b), we extracted three stable mutational signatures (Figures
1A and S1A), which closely resemble the APOBEC, age, and
smoking-associated signatures previously defined (Alexandrov
et al., 2013a). Consistent with our hypothesis that APOBEC-
mediated mutagenesis is particularly important in HPV-driven
tumors, the application of binomial regression showed that the
candidate fractional APOBEC signature per sample was associ-
ated with HPV status, but importantly not with age or smoking
(Figure 1B). This effect was magnified when analysis was
restricted to the more conservative TCW > TTW/TGW (hereafter
TCW > TKW) mutation signature used by Roberts and col-
leagues (Roberts et al., 2013). As expected, smoking levels
were higher among the HPV- HNSCCs (Figure S1B), as was
the fraction of mutations attributable to the smoking signature
(data not shown). We also observed the age-associated muta-
tional signature characterized by C > T mutations at CpG sites.
Despite a lower median age in the HPV+ patients (Figure S1B),
these tumors actually harbored a higher fraction of these muta-
tions. This could be attributable to increased spontaneous
deamination due to the hypermethylation of CpG sites previ-
ously noted in HPV+ HNSCC (Lechner et al., 2013a). The TCW
mutation signature excludes the TCG component of the
APOBEC signature, thus eliminating this potential confounder.
We further sought to establish the enrichment of TCW mutation
signature by calculating a per-sample enrichment score (ES)
(see Experimental Procedures) of C > K mutations at TCW sites
within defined sample fractions of the exome as previously re-
ported (Roberts et al., 2013). Consistent with our other estimates
of the APOBEC signature, the mean ES is higher in HPV+
HNSCC (Figure 1C; 95% bootstrapped confidence interval
[CI]; permutation p value 0.0045). The stronger TCW signature
in HPV+ HNSCC is clear when visualizing the sequence context
surrounding C > K mutations (Figure 1D). APOBEC hyperediting
of viral DNA has been reported in both HPV- and HBV-infected
cells (Vartanian et al., 2008, 2010). To establish whether the
APOBECmutagenic signature may be a general feature of virally
driven cancers, we analyzed 213 exome sequences from the
International Cancer Genome Consortium (ICGC) analysis of
hepatitis virus (HBV or hepatitis C virus [HCV])-associated
hepatocellular carcinoma (HCC) (http://dcc.icgc.org; Project
[LINC-JP] Liver Cancer - NCC, JP). In contrast to HNSCC, we
saw no enrichment for the TCWmotif at sites of C > K mutations
and the overall frequency of TCW mutations was significantly
lower than that seen in either HPV+ or HPV HNSCC (Figure 1D;
data not shown).
APOBEC3B Expression Is Elevated in HPV+ HNSCC but
IsWeaklyCorrelatedwith the Fraction of TCWMutations
in These Tumors
Using TCGA gene expression data generated by RNA-seq, we
examined the expression of APOBEC3B mRNA in the same
samples and found significantly higher expression in HPV+
HNSCC than in HPV HNSCC (p = 3.66 3 1011 by Wilcoxon;
Figure 2A). Whereas the HPV+ tumors have higher APOBEC3B
expression and a higher frequency of TCW mutations, ex-
pression of APOBEC3B is only weakly, albeit significantly,
correlated with TCW mutations across all HNSCC samples
(p = 0.0127; by Spearman’s rho; r = 0.144; Figure 2B). It is clear
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Figure 1. HPV+ HNSCC Harbors a Strong APOBEC-Associated Mutational Signature
(A) Deconvolution of the HNSCC point mutations via nonnegative matrix factorization identifies three signatures closely resembling those previously associated
with APOBEC activity, age, and smoking. Asterisks denote TCW mutations.
(B) Multiple binomial regressions of the fractional APOBEC signatures extracted in (A) as well as the fraction of TCW mutations (TCW > TTW and TCW > TGW)
show a strong association with HPV status, but not with age or smoking history.
(C) Per-sample enrichment analysis of C > K mutations at TCW sites in the genomic neighborhood relative to non-TCW C > K mutations confirms significant
enrichment in HPV+ HNSCCs. The 95% CI was calculated from 10,000 bootstraps of the mean.
(D) Sequence logos illustrate the enrichment of the TCW sequence context at C > K mutations in HPV+ HNSCCs relative to HPV HNSCCs, whereas no such
pattern is evident in viral HCC.
See also Figure S1 and Table S1.
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from this plotted relationship that the observed level of
APOBEC3B can only partially explain the higher fraction of
TCW mutations in HPV+ HNSCC. APOBEC3B expression is
not correlated with the number of background (non-TCW)
mutations in HNSCC (data not shown). We also checked the
expression of the six other APOBEC3 family members that
reside together with APOBEC3B in a gene cluster on chromo-
some 22. With the exception of APOBEC3A, all are significantly
upregulated at the mRNA level in the HPV+ samples (Fig-
ure S2A), but again, expression is only weakly correlated with
TCW mutations (Figure S2B). Furthermore, using viral gene
expression data available for 32 of the 40 HPV+ samples (Table
S1), we did not observe correlations between levels of the
bicistronic transcript encoding the major HPV oncogenes, E6
and E7, and either APOBEC3B expression or TCW mutations
(Figures S3A and S3B).
TCW Mutations Are Correlated with the Background
Mutational Load
From our analysis of APOBEC3B and E6/E7 mRNA levels, it
appears possible that another factor plays the dominant role
in determining the fraction of APOBEC-mediated mutagenesis
in HNSCC. Because HPV+ HNSCC has a significantly lower
number of mutations per exome than HPV HNSCC (Fig-
ure S1C; Agrawal et al., 2011; Stransky et al., 2011), we
Figure 2. TCW Mutations Are Correlated
Weakly with APOBEC3B mRNA Levels but
Strongly with Overall Mutational Load in
HNSCC and BRCA
(A) Box plot displaying APOBEC3B mRNA levels
in HPV and HPV+ HNSCC.
(B–D) Scatterplots showing the relationship
between (B) APOBEC3B mRNA levels and TCW
mutations, (C) TCW and non-TCW mutations in
HNSCC (HPV+ samples, red triangles; HPV
samples, gray diamonds), and (D) TCW and
non-TCW mutations in HER2+ (red triangles) and
HER2 (gray circles) BRCA. Shading around fitted
lines represents 95% CI.
See also Figures S2 and S3 and Table S1.
checked for relationships between total
mutation load and TCW mutations. In
certain HNSCC samples, particularly in
the HPV+ subset, TCW mutations repre-
sent a substantial fraction of total point
mutations, so we examined the rela-
tionship between the number of TCW
mutations and all other point mutations
(non-TCW mutations). The data are
best fit (adjusted R2 = 0.51) by a linear
regression model with a positive slope
for HPV HNSCC (slope 0.24 TCW/
non-TCW) and a separate, steeper line
of fit for HPV+ HNSCC (slope 0.44
TCW/non-TCW), reflecting the higher
fraction of TCW mutations seen in the
HPV+ tumors (Figure 2C). To establish
whether the link between TCW mutations and non-TCW muta-
tions occurs across different tumor types, we analyzed TCGA
data for breast adenocarcinoma (BRCA) (n = 458; Parker et al.,
2009; Cancer Genome Atlas Network, 2012). In BRCA, it is the
HER2-amplified subset that displays the highest level of
TCW mutations (Roberts et al., 2013). Like HNSCC, we
find that, in BRCA, TCW mutations are closely correlated
with non-TCW mutations and the relationship is best fit
(adjusted R2 = 0.34) with a separate steeper line of fit for
HER2+ than HER2 tumors (HER2 = 0.2; HER2+ = 0.49;
Figure 2D).
APOBEC Activity Accounts for a High Fraction of
Mutations in Putative Cancer-Driver Genes in HPV+
Tumors
The E6 and E7 oncoproteins from high-risk HPV strains disable
p53 and pRb tumor suppressor function, causing immortaliza-
tion and cell cycle re-entry, but are not sufficient to affect cellular
transformation. Tumor development in HPV-infected epithelia
therefore requires the acquisition of mutations in cellular genes,
reflected in the considerable latency between HPV infection and
the emergence of carcinoma (McLaughlin-Drubin and Mu¨nger,
2009; Psyrri and DiMaio, 2008). To investigate whether APOBEC
activity directly contributes to tumorigenesis in HPV+ tumors,
we initially focused our analysis on likely driver mutations in
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HNSCC and CESC as determined using MutSig, an algorithm
developed to detect recurrently mutated genes that accounts
for various factors that affect how often a particular gene may
be mutated by chance (Table S2; Broad Institute TCGA Genome
Data Analysis Center, 2013; Lawrence et al., 2013). In HPV+
HNSCC and CESC, the high exome-wide fraction of TCWmuta-
tions is also seen among candidate driver genes, whereas in
HPV HNSCC, the fraction of TCW mutations among MutSig
genes is again much lower than that seen in the HPV+ tumors
(Figure 3A).
This observation prompted us to look in further detail at the
genes that might be mutated by APOBEC and contributing to
Figure 3. PIK3CA Is Mutated at Helical
Domain Hot Spot TCWsites in HPV+HNSCC
and CESC
(A) 95% CI of the TCW mutation fractions in
HNSCC and CESC among MutSig genes.
(B) Location and TCW status of mutations in
PIK3CA among HNSCC and CESC. Black lolli-
pops, TCW mutations; yellow lollipops, non-TCW
mutations.
See also Figure S4 and Tables S2 and S3.
tumor development. Upon ranking all
genes by their TCW mutation content,
as expected, we observed a bias toward
large genes within the top ten; however,
we were struck by the presence of the
PIK3CA proto-oncogene, which encodes
the class 1A phosphoinositide-3-kinase
p110a catalytic subunit, in all three lists
(Table S3). This was of particular interest
to us, because the major oncogenic
PIK3CA mutations have been well char-
acterized and occur at high frequency in
both HPV+ HNSCC and CESC (Lechner
et al., 2013b; Lui et al., 2013; Ojesina
et al., 2014; Vogt et al., 2007). The
most-common and well-studied muta-
tions in PIK3CA lie in two ‘‘hot spots’’:
E542K and E545K in the helical domain
and H1047R in the kinase domain. Upon
inspection of our mutation data, we real-
ized that both E542K (c.1624G > A) and
E545K (c.1633G > A) are caused by
TCW mutations on the opposing strand,
whereas H1047 (typically c.3140A > G)
mutations are not of this type (Figure S4).
We found that, in HPV+ HNSCC and
CESC, the PIK3CA mutations are almost
exclusively (22 of 25) of the TCW type,
with the majority occurring at the helical
domain hot spots, whereas no H1047R
mutations were seen. In HPV HNSCC,
only 22 of 48 PIK3CA mutations were
TCW and we observed eight H1047R
mutations (Figure 3B). Thus, a significant
skew toward TCW mutations in PIK3CA is evident in the HPV+
tumors (chi-square test p = 0.001).
PIK3CA Helical Mutations Are Associated with the
APOBEC Signature in Multiple Cancer Types
Our observations in HPV+ HNSCC and CESC suggest
that APOBEC activity may cause helical domain mutations in
PIK3CA. To test this hypothesis, we investigated the PIK3CA
mutation spectrum in multiple cancers by comparing the
incidence of helical (c.1624G > A; c.1633G > A) versus kinase
(H1047) hot spot mutations. Consistent with our proposi-
tion that APOBEC mediates helical mutations, the tumor
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types with the highest APOBEC signature and highest
APOBEC3B expression levels (bladder carcinoma [BLCA],
CESC, and HPV+ HNSCC; Burns et al., 2013b; Roberts
et al., 2013) showed the highest ratio of helical-to-kinase mu-
tations (Figure 4A). We next related the PIK3CA mutation spec-
trum to the fraction of TCW mutations in each exome and,
again consistent with our model, observed a significant enrich-
ment for TCW mutations in samples harboring helical domain
mutations (Figure 4B; Spearman’s rho 0.71; p 0.01). Our
finding that PIK3CA mutations occur more frequently at the
TCW helical sites in TCW-mutation-enriched tumors strongly
Figure 4. Tumors with Enrichment for
APOBEC Signature Mutations Harbor a
High Proportion of PIK3CA Helical Domain
Mutations
(A) Relative levels of PIK3CA helical and kinase
domain hot spot mutations (as a fraction of the
total number of samples in each cancer type)
across multiple cancer types. BLCA, bladder
carcinoma; COADREAD, colorectal adenocarci-
noma; GBM, glioblastoma multiforme; H, helical;
K, kinase hot spot mutations; STAD, stomach
adenocarcinoma; UCEC, uterine corpus endo-
metrioid carcinoma.
(B) Scatterplot of TCW mutation fraction versus
the fraction of hot spot mutations accounted for by
helical mutations. Shading around fitted lines
represents 95% CI.
suggests that, rather than occurring by
chance, these are indeed mediated by
APOBEC.
DISCUSSION
Our comparison of HPV+ and HPV
HNSCC suggests a strong link between
HPV and APOBEC-mediated mutagen-
esis of cellular genes. Furthermore, the
lack of an association between HBV/
HCV and TCW mutations suggests the
high level of these mutations seen in
HPV-associated tumors is not simply a
vestige of APOBEC enzyme activity asso-
ciated with persistent viral infection. The
relatively high fraction of APOBEC signa-
ture mutations in HNSCC, irrespective of
HPV status, suggests that APOBEC-
mediated mutagenesis is a feature of
certain tumor types and that this activity
is either potentiated or selected for in
the presence of HPV.
We were surprised that increased
expression of several APOBEC3 genes
including APOBEC3B in HPV+ HNSCC
could only partially explain the increased
level of TCW mutations in the HPV+
tumors. This contrasts somewhat with
BRCA, in which APOBEC3B expression is more strongly corre-
lated with C > T mutations and overall mutational loads, but is
consistent with findings in CESC (Burns et al., 2013a; Ojesina
et al., 2014). Nonetheless, the observed fraction of TCW muta-
tions in tumor samples is a late snapshot in tumor progression.
Whereas we do not see evidence that viral gene expression
(E6/E7) or APOBEC levels at this late point are related to the
accumulated TCW fraction, we cannot rule out that we are
observing these fluctuating variables past the crucial phase
during which the mutations are occurring. This scenario
is consistent with a transient hypermutator model recently
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proposed for APOBEC involvement in somatic mutagenesis, in
which the authors note that sustained mutagenic activity is
incompatible with cell viability and would thus be selected
against following the accumulation of key driver mutations (Rob-
erts and Gordenin, 2014). Alternatively, rather than an increased
rate of APOBEC-mediated mutagenesis in HPV+ versus HPV
cells, the elevated fraction of TCW mutations in HPV+ HNSCC
may result from a reduced mutational load of other kinds.
HPV HNSCC typically occurs in heavy smokers, whereas
HPV+ HNSCC is often seen in nonsmokers and harbors less
mutations per tumor (Agrawal et al., 2011; Goon et al., 2009;
Stransky et al., 2011); thus in HPV+ HNSCC, the lack of exoge-
nous mutagens from tobacco smoke may confer a stronger
selection pressure for APOBEC-mediated mutagenesis.
Regardless of mechanism, APOBEC-mediated mutagenesis
is not just a curious passenger mutation phenomenon; rather,
our finding that it mediates driver mutations, including known
oncogenic PIK3CA mutations, suggests it is a vital factor in
HPV-driven tumor development. Furthermore, our data support
a model in which APOBEC activity is the major source of PIK3CA
mutations in multiple cancers, whereas in tumors with low
APOBEC activity, PIK3CA is equally likely to be mutated at the
kinase domain hot spot and the helical domain mutations seen
may be due to other mutational processes that cause C > T
mutations. Whereas APOBECs have previously been implicated
in mutagenesis of putative driver gene sets and both AID and
APOBEC3B cause mutations in TP53 in cultured cells (Burns
et al., 2013a; Matsumoto et al., 2007; Roberts et al., 2013), this
report links their activity to specific oncogenic mutations in
tumors. Our data indicate that whereas mutations in the helical
and kinase domains of PIK3CA cause activation via different
mechanisms (Zhao and Vogt, 2008), the mutational processes
at play in the tumormay in fact be themajor determinant of which
hot spot is mutated. In summary, we have uncovered a critical
role for APOBEC-mediated mutagenesis in HPV-driven tumor
development and identified a specific oncogenic event: the
generation of PIK3CA helical domain mutations, through which
this is mediated, both in HPV+ tumors and in other cancers
that show evidence of high APOBEC activity.
EXPERIMENTAL PROCEDURES
Data Retrieval
BRCA and HCC sequence data were from the Broad Institute’s Genome Data
Analysis Center (GDAC) portal (https://confluence.broadinstitute.org/display/
GDAC/MAF+Dashboard) and the ICGC data portal (ftp://data.dcc.icgc.org/),
respectively. Mutation data for all other tumor types (and RNA-seqV2 data
for HNSCC) were retrieved from the TCGA data portal (https://tcga-data.nci.
nih.gov). HPV status of HNSCC samples as determined by RNA-seq was
obtained from Tang et al. (2013). PIK3CA mutation data were from cBioPortal
for Cancer Genomics (http://www.cbioportal.org/). Duplicate entries were
removed, and data were reduced to point mutations before further processing.
PAM50 annotations for the BRCA samples were retrieved from TCGA portal
at https://tcga-data.nci.nih.gov/docs/publications/brca_2012/. Analysis was
restricted to 458 samples for which the PAM50 subtype was cancer-
associated (Parker et al., 2009; Cancer Genome Atlas Network, 2012).
Point mutation data (including hg19 coordinates) for samples were retrieved
from the maf files, and the sequence context 3 bp up and downstream of each
mutation was retrieved using the Bioconductor BSgenome.Hsapiens.
UCSC.hg19 annotation package.
Mutational Signatures
Mutational signatures were deconvoluted using the Wellcome Trust Sanger
Institute Mutational Signature Framework (Alexandrov et al., 2013b), a method
based on nonnegative matrix factorization. The optimal number of mutational
signatures to extract was determined by searching for maximum stability and
minimum Frobenius reconstruction errors across two to eight candidate signa-
tures using 400 iterations each, whereas the optimal three signatures shown
were subsequently extracted using 1,200 iterations of the algorithm.
Per-Sample Enrichment
ESs were calculated as previously described (Roberts et al., 2013) on a per-
sample basis by comparing the fraction of C > K mutations in and out of the
TCW sequence context to the ratio of cytosines and guanines in and out of
the TCW/WGA sequence context in sample fractions determined using 41
nucleotide windows centered on mutant bases. As the ES score was strongly
skewed, the 95% confidence intervals were defined using 10,000 iterations of
bootstrapping, and p values for enrichment in HPV+ HNSCCs were calculated
using 10,000 permutations (NB t tests on mean difference of ES were also
significant).
Driver Mutations
Lists of genes identified as significantly mutated using MutSig CV0.9 for
HNSCC (https://www.broadinstitute.org/cancer/cga/mutsig; Broad Institute
TCGA Genome Data Analysis Center, 2013; Lawrence et al., 2013) andMutSig
vS2N for CESC were obtained from the relevant Firehose reports on the GDAC
portal. Significantly mutated genes were defined as those with a q value of 0.1
or less.
The list of genes in which missense or nonsense mutations have been caus-
ally implicated in cancer progression was downloaded from the Cancer Gene
Census website (http://www.sanger.ac.uk/research/projects/cancergenome/
census.html).
For code used to analyze all data, see Supplemental Experimental
Procedures.
SUPPLEMENTAL INFORMATION
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